DF_07_OBC_OFC_Layout 1 05/06/2015 15:47 Page 1
DAIRY
MAKE BVD HISTORY AN INNOVATIVE SOLUTION
July 2015
NOW IN YOUR HANDS
Farming finance
FARMER
Barclays’ Oliver McEntyre on lending Pages 70-72 Volume 62 Issue 7
ORBESEAL . MADE FOR MAXIMUM PROTECTION. ®
DAIRY FARMER JULY 2015
A study from 2010 showed that a major hurdle to effective BVD vaccination is ease of use. Only 52% of the farmers in the study gave the two doses required for primary vaccination at the correct interval. Furthermore, just 24% completed the primary vaccination course at the recommended time prior to service leaving these animals and their calves without proper protection1.
Bumper preview of this year’s event
LIVESTOCK EVENT Pages 28-72
• Over 60% of mastitis cases can start during the dry period1 • 50% of high yielding cows may fail to develop a complete keratin teat plug, increasing the risk of bacteria entering the udder2 • OrbeSeal is tried and trusted to reduce mastitis by 35% with over 10 years on farm success3
Next generation for dairy in Lancashire
ON FARM FEATURE
• The silica component of the formulation increases viscosity to create an effective barrier against new infection Don’t take risks during the dry period. Speak to your vet about how OrbeSeal can reduce the cost of mastitis on your farm.
Pages 10-12
Meeting calf rearing targets
YOUNGSTOCK Bovela brings innovation to BVD protection: a L2D (live double deleted) BVD vaccine providing 12 months protection against both BVDV types 1 and 2 from a single shot. Bovela prevents the birth of persistently infected (PI) calves caused by transplacental infection. Vaccination with Bovela can be done from 3 months of age. So now you can finally make BVD history. Ask your vet for more information.
Herd protection made simple
Reference: 1. Meadows (2010) Cattle Practice 18(3): 202-215 Advice on the use of Bovela or other therapies should be sought from your veterinary surgeon. Bovela lyophilisate and solvent for suspension for injection for cattle contains modified live BVDV-1, non-cytopathic parent strain KE-9: 104.0 –106.0 TCID50, Modified live BVDV-2, non-cytopathic parent strain NY-93: 104.0 –106.0 TCID50. UK: POM-V IE: POM. Further information available from Boehringer Ingelheim Limited, Vetmedica, Bracknell, Berkshire, RG12 8YS, UK. Tel: +44 (0)1344 746959. Technical enquiries: +44 (0)1344 746957. Email: vetmedica.uk@boehringer-ingelheim.com. Date of preparation: Feb 2015. AHD8395. Use Medicines Responsibly (www.noah.co.uk/responsible)
1. Mütze K, et al. The effect of dry cow antibiotic with and without an internal teat sealant on udder health during the first 100 days of lactation: a field study with matched pairs. J Dairy Res. 2012 Nov;79(4):477-84 2. Dingwell RT et al. (2004). Association of cow and quarter-level factors at drying-off with new intramammary infections during the dry period. Prev Vet Med.;63(1-2):75-89 3. Rabiee AR & Lean IJ. The effect of internal teat sealant products (Teatseal and Orbeseal) on intramammary infection, clinical mastitis, and somatic cell counts in lactating dairy cows: A meta-analysis. Dairy Sci. 96 :6915–6931 OrbeSeal contains 65% bismuth subnitrate. Withdrawal period: Zero days: POM-V . Further information is available on the product SPC or contact your veterinary surgeon or contact Zoetis UK Ltd, Walton Oaks, Dorking Road, Walton on the Hill, Tadworth, Surrey, KT20 7NS. Customer Support 0845 3008034. www.zoetis.co.uk Always seek the advice of your medicines provider. Use medicines responsibly (www.noah.co.uk/responsible) AH246/15
Pages 24-27
GOOD EVANS Pages 78-79
Tip of the month: Farmhouse tax net widens – p80 1
0
12:30